

ChromaDex to Join Russell 2000® Index

ChromaDex continues to drive innovation and growth with its proprietary Tru Niagen® supplement, backed by strong financial performance and a robust intellectual property portfolio

LOS ANGELES – ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced its inclusion in the Russell 2000® Index as part of the annual reconstitution of the Russell stock indexes. This inclusion will be effective at the opening of U.S. equity markets on Monday, July 1, 2024, based on the preliminary list of additions posted on Friday, May 24, 2024.

Rob Fried, CEO of ChromaDex and Founder of Tru Niagen commented, “Joining the Russell 2000 Index reflects our sustained growth and leadership in NAD+ research. Tru Niagen® is the gold standard NAD+ supplement, backed by scientific rigor, the highest quality standards, and a robust intellectual property portfolio. This achievement underscores our commitment to driving long-term value for our shareholders as we expand our global footprint, innovate with new products, and advance the science of healthy aging.”

The annual Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of Friday, June 28, 2024, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which lasts for one year, guarantees automatic inclusion in either the large-cap Russell 1000® Index or the small-cap Russell 2000® Index, along with the appropriate growth and value style indexes. FTSE Russell primarily determines index membership based on objective market-capitalization rankings and style attributes.

The ChromaDex team, comprised of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors, which contributes to age-related changes in health and vitality.

Setting the benchmark as the gold standard in scientific rigor and quality in the dietary supplement space, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen® (patented nicotinamide riboside, or NR). Clinically proven to increase NAD+ levels, Niagen is the most efficient and superior-quality NAD+ booster helping people transform the way they age.

Food-grade Niagen is available in the consumer dietary supplement Tru Niagen®, the number

one healthy-aging oral NAD+ supplement in the United States*, and through partnerships with global retailers and distributors. Pharmaceutical-grade Niagen will soon be available through FDA-registered 503B outsourcing facilities and will be administered at clinics pursuant to a valid prescription.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately \$10.5 trillion in assets are benchmarked against Russell's U.S. indexes. FTSE Russell, a leading global index provider, administers these indexes.

For more information on the Russell 2000[®] Index and the Russell indexes reconstitution, please visit the Russell Reconstitution Section on the FTSE Russell website. Learn more about ChromaDex by visiting www.chromadex.com.

Forward Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to ChromaDex's inclusion in the Russell 2000[®] Index as part of the annual reconstitution of the Russell stock indexes. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

About ChromaDex:

ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, comprised of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality. Setting the benchmark as the gold standard in scientific rigor and quality in the dietary supplement space, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen® (patented nicotinamide riboside, or NR). Clinically proven to increase NAD+ levels, Niagen is the most efficient and superior-quality NAD+ booster helping people transform the way they age.

Food-grade Niagen is manufactured by ChromaDex and is available in the consumer dietary supplement Tru Niagen®, the number one healthy-aging oral NAD+ supplement in the United States* (available at www.truniagen.com). Pharmaceutical-grade Niagen will be available through FDA-registered 503B outsourcing facilities and will be administered at clinics pursuant to a valid prescription (www.niagenplus.com).

ChromaDex's robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com, to which ChromaDex regularly publishes copies of its press releases, news, and financial information.

**Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024).*

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20240701261918/en/>

ChromaDex Media Contact:

Kendall Knysch, Senior Director of Media Relations & Partnerships

310-388-6706 ext. 689

kendall.knysch@chromadex.com

ChromaDex Investor Relations Contact:

Ben Shamsian

Lytham Partners

646-829-9701

shamsian@lythampartners.com